GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

Del Bufalo, Francesca; De Angelis, Biagio; Caruana, Ignazio; Del Baldo, Giada; Antonietta De Ioris, Maria; Serra, Annalisa; Mastronuzzi, Angela; Giuseppina Cefalo, Maria; Pagliara, Daria; Amicucci, Matteo; Li Pira, Giuseppina; Leone, Giovanna; Bertaina, Valentina; Sinibaldi, Matilde; Di Cecca, Stefano; Guercio, Marika; Abbaszadeh, Zeinab; Iaffaldano, Laura; Gunetti, Monica; Iacovelli, Stefano; Bugianesi, Rossana; Macchia, Stefania; Algeri, Mattia; Merli, Pietro; Galaverna, Federica; Abbas, Rachid; Carmen Garganese, Maria; Felicia Villani, Maria; Stefania Colafati, Giovanna; Bonetti, F; Rabusin, Marco; Perruccio, Katia; Folsi, Veronica; Quintarelli, Concetta; Locatelli, Franco

doi:10.1056/nejmoa2210859

Public

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

Published in New England Journal of Medicine • Apr 5, 2023

Authors:

Francesca Del Bufalo

Biagio De Angelis

Ignazio Caruana

Abstract

Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. Download a PDF of the Research Summary. In an academic, phase 1–2 clinical trial, we enrolled p...

Subject

Medicine

Refractory (planetary science)

Neuroblastoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!